- Home
- ALL vs ARGX Comparison
ALL vs ARGX Comparison
Compare ALL & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALL | ARGX |
|---|---|---|
| Founded | 1931 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.7B | 58.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALL | ARGX |
|---|---|---|
| Price | $255.73 | $977.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 19 |
| Target Price | $226.65 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 1.4M | 216.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 124.01 | N/A |
| EPS | ★ 21.73 | N/A |
| Revenue | ★ $67,685,000,000.00 | N/A |
| Revenue This Year | N/A | $44.39 |
| Revenue Next Year | $5.96 | $20.84 |
| P/E Ratio | ★ $11.84 | $33.69 |
| Revenue Growth | ★ 5.58 | N/A |
| 52 Week Low | $188.08 | $661.85 |
| 52 Week High | $277.22 | $1,072.75 |
Technical Indicators
Market Signals| Indicator | ALL | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 49.06 |
| Support Level | $254.46 | $830.58 |
| Resistance Level | $257.67 | $1,072.75 |
| Average True Range (ATR) | 4.41 | 22.49 |
| MACD | -0.54 | -11.44 |
| Stochastic Oscillator | 44.42 | 2.85 |
Price Performance
Historical ComparisonAbout ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.